Abstract:Objective To investigate the clinical features and mutations of the FAH gene.Method Clinical records of two cases were collected,and diagnosis was made according to the diagnostic criteria of the International Organization for Rare Disorders (NORD).Genomic DNA was extracted from peripheral blood leukocytes with QIAamp(R) DNA Mini Kit.The DNA extracts were subjected to direct sequencing for 14exons together with adjacent fragments of FAH gene using ABI Prism 3730 Genetic Analyzer (Applied Biosystems,Foster City,CA) after PCR based on genomic DNA.The mutation source was verified by analyzing parents' exons corresponding to patients' mutation exons.The homology between human FAH enzyme and that of other species was surveyed using software Clustal X (European Bioinformatics Institute,Hinxton,Saffron Walde,UK).Polyphen (Polymorphism Phenotyping),available online,were used to predict possible impact of an amino acid substitution on structure and function of FAH enzyme.Polyphen calculates position-specific independent counts (PISC) scores for two amino acid variants in polymorphic position.A PISC scores that differ by ＞ 2 were regarded as indicating the probability of damaging variants.Result Patient 1 was a 5 months and 21 days-old boy who suffered from persistent diarrhea,hepatomegaly,ascites; Alpha-fetoprotein ＞ 1210 μg/L,levels of tyrosine in blood and succinylacetone in urine were 110.8 μmol/L and 83.7 μmol/L.His sister suffered from tyrosinemia type 1.Direct sequencing showed a G to A transition in CDS position 455 and 1027.He was compound heterozygous for the mutation c.455G＞ A/c.1027G ＞ A,which predicts a change from tryptophan to a stop codon (TGG＞ TAG) at position 152 (W152X) and a change from glycine to arginine (GGG ＞ AGG) at position 343 respectively.Patient 2 was a 6 year and 1 month-old girl with late-onset rickets who had signs of hepatosplenomegaly,rachitic rosary,windswept knees.Hypophosphatemia and alkaline phosphatase 1620 IU/L were detected.Alpha-fetoprotein 412.8 μg/L,levels of tyrosine in blood and succinylacetone in urine were 835.8 μmol/L and 27.48 μmol/L.Rickets did not improve after administration of calcium and vitamine D3.She is homozygous for the mutation c.1027G ＞ A/c.1027G ＞ A,which predicts G343R.The parents were mutation carriers.Analysis by Clustal X on the alignment of amino acids residual reservation among different species showed that the locative amino acid was highly conserved.Polyphen software predicted G343R was probably damaging (PISC score 3.235).Conclusion Children with tyrosinemia type 1 can have manifestations of persistent diarrhea or late-onset tickets.Physical examination can reveal hepatosplenomegaly,laboratory tests indicate markedly elevated serum concentration of alpha-fetoprotein and alkaline phosphatase in plasma and succinylacetone in urine,other members in family may have tyrosinemias or parents are consanguineous.Mutations c.455G ＞A and c.1027G ＞ A can be detected in FAH gene of Chinese children.

Homologous recombination mediates stable Fah gene integration and phenotypic correction in tyrosinaemia mouse-model

487. Therapeutic Genome Editing by Combined Viral and Non-Viral Delivery of CRISPR System Components to the Mouse Liver

Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1

A Facile Method for Somatic, Lifelong Manipulation of Multiple Genes in the Mouse Liver

Identification and Functional Characterization of a Novel Homozygous Intronic Variant in the Fumarylacetoacetate Hydrolase Gene in a Chinese Patient with Tyrosinemia Type 1.

Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I.

A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I

Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats

Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

Expression and processing of mature human frataxin after gene therapy in mice

CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

Mutation analysis of FAH gene in patients with tyrosinemia type 1

Developing Gene Therapy for Mitigating Multisystemic Pathology in Fabry Disease: Proof of Concept in an Aggravated Mouse Model

TTR exon-humanized mouse optimal for verifying new therapies for FAP

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

Fumarylacetoacetate Hydrolase Knock-Out Rabbit Model for Hereditary Tyrosinemia Type 1

Modeling HBV Infection and Therapy in Immunodeficient NOD-Rag1-/-IL2RgammaC-null (NRG) Fumarylacetoacetate Hydrolase (FAH) Knockout Mice with Human Chimeric Liver